{
    "nctId": "NCT02550080",
    "officialTitle": "A Phase IV, Randomised, Multicentre, Double-blind, Study to Evaluate the Clinical Utility of Prospective Genetic Screening (HLA-B*1301) for Susceptibility to Dapsone Hypersensitivity Syndrome",
    "inclusionCriteria": "* Diagnosed with cutaneous vasculitis, urticaria, psoriasis, acne, bullous skin diseases, sterile pustulosis, leprosy, pneumocystis pneumonia and any other patients who need dapsone administration.\n* Subjects are dapsone-naive.\n* All subjects must have a clinical need for treatment with dapsone that precedes the decision to participate in the study.\n* All subjects are willing to complete the 6-weeks period clinical trial.\n* All subjects are written informed consent.\n* Must have minimum age of 18 Years\n* Must have maximum age of 65 Years",
    "exclusionCriteria": "* Has previously received Dapsone therapy.\n* The subject or any of their healthcare providers is aware of the subjects HLA type.\n* Has been diagnosed with Glucose-6-phosphate dehydrogenase deficiency or methemoglobin reductase deficiency\n* Satisfies any contraindications or restrictions to Dapsone therapy as listed in the product labels.\n* Current severe illness, including heart, liver and renal failure, major organ allograft, malignancy requiring parenteral chemotherapy that can not be discontinued for the duration of the trial, or any other conditions which, in the opinion of the Investigator, would make the patient unsuitable for the study.\n* Any laboratory abnormality at Screening which, in the opinion of the Investigator, should preclude the subject's participation in the study \\[alanine aminotransferase (ALT), glutamic oxaloacetic transaminase(ALT), et al).\n* Pregnant women or women who are breastfeeding.\n* Subject is, in the opinion of the Investigator, unable to complete the 6 week Observation period and the EPT assessments as required.\n* A positive result for HLA-B\\*1301 in those subjects randomised to the genetic screening arm."
}